Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA

Documenti analoghi

• Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
  di: Fautrel, B, et al.
  Pubblicazione: (2019)
• Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
  di: Taylor, P, et al.
  Pubblicazione: (2019)
• Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
  di: Fautrel, B, et al.
  Pubblicazione: (2017)
• Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
  di: Taylor, P, et al.
  Pubblicazione: (2019)
• Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
  di: Fautrel, B, et al.
  Pubblicazione: (2018)